US insurers to target antibiotics overRxing

9 April 2001

A group of 24 US health insurers is planning a campaign to combatexcessive and unnecessary prescribing of antibiotics. The firms, which include such majors as Aetna and Cigna, say they will use posters, pamphlets and possibly print media and television advertising to warn of the dangers of inappropriate use of the drugs, and will also use the data they hold on doctors' prescribing habits through their processing of pharmacy claims to effect change, reports the Wall Street Journal.

Over 40% of the 100 million courses of antibiotics prescribed in the USA each year are unnecessary, including an estimated 17 million prescribed to treat the common cold, notes the report.

Aetna, which spends about $500 million annually on antibiotics for its 20 million enrollees, says the campaign will include no disciplinary action against doctors who are revealed to be prescribing excessively or unnecessarily. Rather, it believes that comparisons with their peers will encourage them to change their habits.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight